IL6 and ovarian carcinoma: Subsequent analysis showed increased levels of IL-6 in ovarian cancer patient ascites, and treatment using anti-IL-6 antibodies showed decreased invasion and migration, decreased mesenchymal phenotype, and decreased activation of the JAK/STAT3 downstream signalling [26].